WuXi AppTec subsidiary STA Pharmaceutical have completed an expansion of its integrated R&D and commercial site in Changzhou, China, to accommodate 200 scientists and a new pilot plant.
The company provides an open-access R&D capability and technology platform for small molecule process development and manufacturing.
The 39-acre site, which was officially opened in March 2016, includes 160 process chemists, 40 analytical chemists, and a special group of crystallization technology engineers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze